AI Science Tracker

TARSA prioritizes peptides active against breast cancer cells

University of British Columbia; University of Ottawa; Mila, Université de Montréal; Simon Fraser University · 27 Nov 2025 · medicine

Discovery

TARSA prioritizes peptides active against breast cancer cells

TARSA combines reinforcement learning and posterior sampling to search a 36-million-sequence library of experimentally resolved helical peptides. The study reports that 15 of 105 selected candidates showed cytotoxic activity against triple-negative breast cancer cells in vitro; the three leads were further tested against other breast cancer subtypes and peripheral blood cells. The source also reports toxicity against normal breast cells, so these findings do not establish therapeutic safety or clinical efficacy.

Technology: TARSA reinforcement learning; MCMC posterior sampling; learned cytotoxicity models

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: 105 selected peptides were experimentally evaluated; 15 showed activity in the reported breast-cancer-cell assays.
  • Still unknown: Cell-culture results do not establish therapeutic efficacy; the source reports normal-breast-cell toxicity, and independent replication remains unknown.
  • AI role: TARSA reinforcement learning and posterior sampling guide exploration of a very large peptide library, with learned potency/toxicity models used to select candidates for assays.

Evidence sources: https://www.nature.com/articles/s41467-025-66748-y

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Publisher full article including publication date, model description, methods and experimental results..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.